NABCO Offers New Edition of Its Breast Cancer Resource List

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 12
Volume 4
Issue 12

NEW YORK--The National Alliance of Breast Cancer Organizations (NABCO) has just released the 1995/96 edition of the NABCO Breast Cancer Resource List. This year's 70-page List, supported by an educational grant from Glaxo Wellcome Inc., includes more than 2,000 books, brochures, videos, hotlines, and support groups useful for women and health professionals.

NEW YORK--The National Alliance of Breast Cancer Organizations(NABCO) has just released the 1995/96 edition of the NABCO BreastCancer Resource List. This year's 70-page List, supportedby an educational grant from Glaxo Wellcome Inc., includes morethan 2,000 books, brochures, videos, hotlines, and support groupsuseful for women and health professionals.

The organization said that more than 30,000 copies of the Listwill be distributed to breast cancer survivors and medical offices.

The new NABCO Breast Cancer Resource List may be orderedfrom NABCO, 9 East 37th Street, New York, NY 10016, by enclosinga check for $3.00 and a self-addressed mailing label. Physiciansmay ask for copies with the "Display Copy" legend foruse in waiting rooms.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content